Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2012

View Archived Issues

New phase I data disclosed on KX2-391 in chemotherapy-naive bone-metastatic CRPC

OMP-59R5 well tolerated in phase I study

CalciMedica describes new class of immunomodulators

Clinical studies assess daily and twice-daily dosing of golvatinib

CHMP schedules hearing for Vivus' Qnexa MAA

Novel candidate cancer therapies created at Aurigene Discovery Technologies

Research alliance reached for carfilzomib and oprozomib

Phase III elagolix study begins in endometriosis

MebioPharm set to launch phase II/III MBP-426 trial

Portola Pharmaceuticals presents new SYK inhibitors

Dr. Reddy's Laboratories enters worldwide biosimilars collaboration

PharmaGap provides update on lead program

Roche expands gantenerumab trial in prodromal Alzheimer's disease

Preclinical study validates new target for resistant tumors

Phase I study evaluates peptide vaccine including cancer/testis antigens

Bayer designs novel guanylate cyclase activators

FDA sends complete response letter for ridaforolimus NDA

BioDiem to license new vaccine technology from Australian university

Kythera receives milestone payment from Bayer in ATX-101 collaboration

Research at U.S. university yields new anticancer agents

ProFibrix commences pivotal FINISH-3 study

Starpharma provides enrollment update for pivotal VivaGel studies

AVEO and Astellas planning new phase II study in RCC

Novel protein kinase inhibitors divulged

SDF-1 inhibition may limit transplant vasculopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...